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ABSTRACT
Objective: Thrombolysis within the ﬁrst 3 hours after the onset of symp-
toms of a stroke has been shown to be a cost-effective treatment because
treated patients are 30% more likely than nontreated patients to have no
residual disability. The objective of this study was to calculate by means of
a discrete event simulation model the budget impact of thrombolysis in
Spain.
Methods: The budget impact analysis was based on stroke incidence rates
and the estimation of the prevalence of stroke-related disability in Spain and
its translation to hospital and social costs. A discrete event simulation model
was constructed to represent the ﬂow of patients with stroke in Spain.
Results: If 10% of patients with stroke from 2000 to 2015 would receive
thrombolytic treatment, the prevalence of dependent patients in 2015
would decrease from 149,953 to 145,922. For the ﬁrst 6 years, the cost of
intervention would surpass the savings. Nevertheless, the number of cases in
which patient dependency was avoided would steadily increase, and after
2006 the cost savings would be greater, with a widening difference between
the cost of intervention and the cost of nonintervention, until 2015.
Conclusion: The impact of thrombolysis on society’s health and social
budget indicates a net beneﬁt after 6 years, and the improvement in health
grows continuously. The validation of the model demonstrates the
adequacy of the discrete event simulation approach in representing the
epidemiology of stroke to calculate the budget impact.
Keywords: budget impact analysis, pharmaceuticals, simulation models,
stroke.
Introduction
Stroke results in a marked mortality rate at the time of the acute
event and during the following years [1]. Furthermore, a conse-
quence of brain damage in one-third of patients is the develop-
ment of a disability that persists over a period of time [2,3].
Thrombolysis, notwithstanding its limited inﬂuence in reducing
mortality, is the only speciﬁc treatment for the acute event that
improves the prognosis in patients who have had an ischemic
type of stroke [2,4]. It has been shown to be cost-effective within
the ﬁrst 3 hours after the onset of symptoms of a stroke, despite
its high cost as a pharmaceutical, because treated patients are
30% more likely than untreated patients to have no disability at
12 months [5–7]. In Spain approximately 60,000 patients with
ﬁrst-ever stroke are hospitalized each year [3]. Given this volume,
decision-makers need an economic approach to fully understand
the impact of the introduction of thrombolysis on a population
level in terms of the budget of the Spanish health system and the
resulting health gain [8,9]. Mauskopf has described budget
impact analysis (BIA) as an estimate of the impact of a new
treatment on annual costs, annual health, and other outcomes of
interest for the ﬁrst, second, and subsequent years after the
introduction of the new product for a national or a health-plan
population [10]. With a similar purpose, but from a different
approach, the business literature uses the concept of return of
investment. This term indicates the cash ﬂow over a speciﬁed
period of time. As a measure of proﬁtability, BIA shows the net
trade-off between cost and revenues of a project in relationship
with the investment [11]. The BIA of stroke treatments relies on
both incidence and prevalence [12–14]. In the assessment of the
burden of neurologic diseases, the societal perspective must be
applied because the management of the long-term consequences
in terms of disability entails an important consumption of
resources. The calculation of these costs is based on the change in
prevalence of disabled patients [14].
In practice, BIA is usually carried out on the basis of the
pharmaceutical costs by straightforward spreadsheets. These
costs are usually elaborated for submission to the government
drug agency in the process of registering a new treatment. The
lack of a standard and well-accepted methodology has led to a
scarcity of these studies in the scientiﬁc literature. In recent years,
however, different scientiﬁc societies and governmental agencies
have recognized the important role that BIA can play as a
complementary tool for cost-effectiveness analysis in the
decision-making process for new technologies [15–17]. At the
same time, different authors have published guidelines to
promote good practices [18–20].
In the ﬁeld of economic evaluation, different approaches for
disease modeling have been applied. Markov models have
become the most popular technique because their management of
a cohort produces an output that ﬁts well with the needs of
cost-effectiveness studies [20,21]. Modeling of stroke for BIA
requires different outputs because the key parameter is the popu-
lation prevalence. Discrete event simulation (DES), which is
widely used in business and engineering, is an alternative to
Markov models. It has been applied in health services to evaluate
cases on waiting lists for surgical procedures. Nevertheless, the
ﬂexibility of DES in the representation of different stages of
disease and in the calculation of various outputs has promoted its
growing presence in the economic evaluation of health interven-
tions [22,23].
The objective of this study was to calculate the BIA of throm-
bolysis in the treatment of stroke in Spain by means of a DES
model that represents the ﬂow of patients with stroke in the
Spanish population.
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Methods
The BIA of stroke treatments relies on both incidence and preva-
lence. The incidence of stroke is required to estimate the inter-
vention costs, and it can be obtained from the Minimum Data Set
of the health system; the calculation of costs related to the care of
disabled individuals is based on its prevalence. We constructed a
DES model to represent the natural history of stroke in the
Spanish population to calculate the prevalence of stroke-related
disability from 2000 to 2015.The number of disabled subjects
was obtained twice; the ﬁrst considered that thrombolysis was
not used (base conditions), and the second took into account that
from the year 2000, 10% of all strokes were treated with the
drug recombinant tissue plasminogen activator (rt-PA) within 3
hours of the onset of symptoms, according to the conditions of
the National Institute of Neurological Disorders and Stroke
(NINDS) study. In this clinical trial, it was found that this inter-
vention improved the prognosis because treated patients were
30% more likely than untreated patients to have no disability [4].
The difference in prevalence estimates between the two scenarios
(base conditions and treatment conditions) allowed the calcula-
tion of the amount of disability avoided and, therefore, the cost
savings.
Conceptual Model
Figure 1 shows a simpliﬁed representation of the model with
Arena (Rockwell, Milwaukee, WI) simulation elements. The
model begins with the occurrence of a ﬁrst-ever stroke. This
acute event could evolve to three conditions: death, disability, or
autonomy. The prognosis for patients who survive a stroke is
characterized by a higher mortality risk than that occurring in the
general population for two reasons. First, the risk of a recurrent
stroke entails high lethality, and, second, the mortality risk from
other causes is also increased. Incidence is derived from the
number of ﬁrst-ever strokes occurring by year in a population,
and it has been estimated that these strokes represent 75% of the
total number registered [2,3]. Prevalence is an instant measure
deﬁned as the number of individuals in a population who remain
alive after having suffered a stroke [13]. Therefore, prevalence
changes continuously through time, but we assumed that it
remained constant within each year to simplify the presentation
of results [13].
DES Model: Elements and Outputs
In economic evaluation, Markov models are still the standard
tool to carry out cost-effectiveness analysis. They allow the cal-
culation of the survival for each health state of a cohort accord-
ing to two sets of probabilities to obtain the incremental cost-
effectiveness ratios [5,21,22]. This approach is adequate when
the objective is to estimate the efﬁciency of a new intervention.
To obtain the population prevalence, however, the model must
take into account all the cohorts that include living individuals
with the feature of interest. We applied DES to represent the
epidemiology and the clinical course of stroke in the Spanish
population on the basis of other examples from the literature that
use DES to represent the natural history of disease [23–26]. The
main advantage of DES methods is that they can accommodate
many entities with different characteristics at the same time. This
ﬂexibility enables the inclusion of all the different age cohorts
contained in the population of interest. As opposed to Markov
models, time ﬂows continuously, and it is not split discretely in
cycles. As the model runs and the time advances, each individual
or entity experiences changes related to its attributes. These
changes are recorded, and, in the end, they determine the number
of incidental events and the number of entities of speciﬁc interest
(disability prevalence) across time. The probability of events and
the duration of processes are derived from random and indepen-
dent sampling from theoretical and empirical distributions [23].
This approach permits the evaluation of thousands of entities
and, therefore, assessment of the whole population of interest
simultaneously. The 10th version of Arena software was used to
build the model [27].
Given the epidemiologic differences, separate models for
men and women were constructed. The model began with an
incident cases generator that incorporated patients with ﬁrst-
ever stroke into the system. The incidence was reproduced
through a schedule beginning in 1970 and ending in 2015. The
ﬁrst 30 years were the warming-up period, and the results were
analyzed from 2000 to 2015. Incidental rates from hospital
registers in Spain from 1995 to 2005 were used. We applied the
ﬁgures from 1995 to the previous years. On the basis of the
literature, we considered that 75% of all patients with stroke
seen in Spanish hospitals had ﬁrst-ever strokes [2,3]. The inci-
dence from 2006 to 2015 was estimated by applying 2005 rates
for sex and age to the population predictions of the Spanish
Statistics Institute.
In DES, each case is called an entity. At entry to the system,
each entity had to be described according to its individual
attributes and the occurrence of events. First of all, age was
assigned randomly according to the empirical distribution drawn
from the Spanish Health Statistics Unit in association with the
number of strokes by age. A Gompertz distribution was used to
randomly assign time until death in function of age. The param-
eters of the Gompertz distribution were calculated from Spanish
all-cause death rates [28], and a relative risk of 2.6 [6,7] was
applied to take into account the excess mortality risk from other
causes in patients with stroke. The Gompertz distribution param-
eters for the general population were adjusted by that relative
risk to obtain the parameters for the population of patients with
stroke. The formula used a random factor (u) to obtain values
from probabilities and natural logarithms (Ln).
Distribution parameters appear in Table 1.
Time until event = × − × −( ) ×( )− ×1 1 1β βα βLn Ln u e Age
Time until recurrent stroke is a characteristic of each patient
with stroke, and it has a key role in deﬁning the path that an
entity follows in the system. The standard approach applied in
Markov models passes by obtaining a probability, but in DES a
time to event is needed. We also applied a Gompertz distribution
Incidence Assign age and times
Stroke
distribution
Recurrent
stroke?
Disabled
Autonomous
Death
Figure 1 Simpliﬁed diagram of the model.
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with parameters (Table 1) obtained by calibration to determine
the duration of that process.
We interpreted both parameters, time until death and time
until recurrent stroke, as concurrent risks. The model managed
the concurrent risks by introducing a function obtained by com-
parison of both times; this means that the next event to occur was
the ﬁrst in time. As in real life, these concurrent risks were
mutually exclusive. Recurrent strokes could only happen if they
were realized within the survival time. The probabilistic charac-
teristic of the model means that for each entity a value was drawn
from the two speciﬁc distributions to let chance decide which
event, death or recurrent stroke, happened ﬁrst.
The use of beta distributions to manage the evolution from
stroke and recurrent stroke to three outcomes (death, autonomy,
or disability) poses important problems. This challenge was
handled using the Briggs method, which is based on applying
Dirichlet distributions, the parameters of which appear in
Table 1 [3,5,29]. Distributions changed according to the type of
stroke: ﬁrst-ever or recurrent. The only constraint was that dis-
abled patients could not become autonomous after a recurrent
event. Patients with the conditions of disability and autonomy
were classiﬁed by age to obtain the prevalence by age each year.
Disabled patients had a Barthel index lower than 95 as deﬁned in
the NINDS study [4,30]. The model was built to manage the ﬂow
of entities among the different age groups before the occurrence
of an event, such as recurrent stroke or death. This characteristic
enables the calculation of prevalence by age group for each year
of the running time from 2000 to 2015.
The outputs of the model were the incidence of ﬁrst-ever and
recurrent strokes, the survival time by age of the patients, and the
prevalence of disabled and autonomous individuals by year.
These statistics were obtained by different methods. The number
of events, such as incidence of ﬁrst-ever and recurrent strokes,
was captured by counters placed in opportune points. The model
recorded times of entry to and exit from the system for each
entity to calculate life expectancy by age group and sex. Preva-
lence estimation requires another method because it changes
continuously and the required outputs are intermediate measure-
ments. The estimate for each year was recorded and exported to
Excel while each replication was running. The model systemati-
cally ran 1000 replications to obtain conﬁdence intervals for
fewer than 10 individuals for each age group. The criterion for
stopping each replication was arrival at the end of 2015.
Validation
The validation of the model was carried out by comparing the
outputs with the parameters that were associated with the epi-
demiology of stroke in Spain. The life expectancy of patients with
stroke according to sex and age was compared with the values
from the literature [12,31]. Given the model’s structure, the
proportion and age-group distribution of those having recurrent
strokes constituted key elements. Cumulative incidence was also
recorded from 2000 to 2015 to check the quality of the schedule
applied in the introduction of cases into the system. To validate
the prevalence results, we ﬁrst compared them with the results of
the application of epidemiologic data from the Spanish popula-
tion to a Markov model that reproduced the natural history of
stroke at a population level [12]. A second validation was imple-
mented by comparing our ﬁndings with the ﬁgures that resulted
from applying to the Spanish population the rates of prevalence
by age group and sex that we obtained from a population register
in Auckland [31].
BIA for Years 2000 to 2015
The cost of thrombolysis was based on stroke incidence, the
percentage of patients treated, and the unitary cost of treatment.
From previous studies, we retrieved the cost of the drug Alteplase
(Actilyse, Boehringer Ingelheim, Ingelheim, Germany) (€1295)
and the cost of a 1-day stay in the intensive care unit (€1399) [5].
Thrombolysis increases in stroke patients the risk of intracranial
hemorrhage by 4.5% [32]. Therefore, the cost of its hospital stay
(€6130 by hemorrhage) was projected for each treated patient by
adding €354. To obtain the cost of thrombolysis alternative, we
assumed that 10% of all patients with stroke were treated with it.
The calculation of the cost savings relied on the calculation of
the prevalence of dependent patients. Each year, the beneﬁt was
calculated according to the difference in the number of dependent
patients between both alternatives, those treated and those not
treated with thrombolysis. Thrombolytic treatment in patients
with stroke can be introduced into the model by multiplying the
disability risk after stroke by a relative risk of 0.732, according to
Table 1 Model parameters
Parameter Source Mean Distribution Parameters
First-ever stroke incidence Entity: stroke Stroke rates by sex and age (HSU) Empirical
Age Assign age Stroke rates by sex and age (HSU) Empirical
Time until death by other causes
with RR = 2.67
Assign time Death rates by sex and age (INE) Gompertz Men a = RR*e-9.36
b = 0.085
Women a = RR*e-12
b = 0.112
Time until recurrent stroke Assign time Calibration Gompertz Men a = e-9.0
b = 0.085
Women a = e-9.7
b = 0.090
From ﬁrst-ever stroke to Autonomous
Disabled
Death
Gipuzkoa Study [8,18] 0.4566
0.2704
0.2730
Dirichlet Gamma (179,1)
Gamma (106,1)
Gamma (107,1)
From ﬁrst-ever stroke to
(with thrombolysis)
Autonomous
Disabled
Death
Gipuzkoa Study [8,18]
NINDS study [4]
0.5291
0.1979
0.2730
Dirichlet Gamma (207,1)
Gamma (78,1)
Gamma (107,1)
From recurrent stroke to Autonomous
Disabled
Death
Gipuzkoa Study [8,18] 0.3432
0.3657
0.2910
Dirichlet Gamma (46,1)
Gamma (49,1)
Gamma (39,1)
HSU, Health Statistics Unit in the Spanish Government; INE, Statistics Spanish Institute; RR, relative risk.
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the NINDS study [4]. Mortality and recurrent stroke rates
were the same with and without thrombolytic treatment [4]. In
2000, the cost of care of a disabled patient amounted to €15,295,
and the care of an autonomous patient required €4,941 [5]. The
1-year savings for the whole population resulted from the mul-
tiplication of that difference (€10,354) by the number of depen-
dent subjects that were avoided. These ﬁgures come from a study
that followed a sample of 535 Spanish stroke patients for a year.
Dependency for activities of daily life was evaluated by means of
the Barthel index. Costs of formal and informal care were cal-
culated following a bottom-up approach and a diary survey
method. Formal care included nursing homes and home care
carried out by social services. The support given by families was
converted to informal care cost [5]. The beneﬁt in effectiveness
was based on the different utilities for the autonomous (0.7360)
and disabled (0.4013) conditions measured with the EuroQol
instrument (EQ-5D) instrument [5]. As the BIA presents ﬁnancial
streams over time, it is not necessary to discount the costs.
According to the recommendations in the guidelines for a BIA,
however, the computational framework was constructed so that
the decision-maker could readily discount these results according
to local practice [20]. Given the speciﬁc features of the older
population, a subgroup analysis was carried out by taking into
account only individuals older than 70 years. Current ﬁgures in
Spain for patients with stroke receiving thrombolysis are closer
to 5% than to 10%. Therefore, we also calculated the BIA,
assuming that only 5% would receive treatment. Nevertheless,
we maintained the 10% for the base case to underline that only
a ﬁgure of at least 10% can be accepted as a satisfactory objective
for the stroke population level of use.
Results
Validation Outcomes
Table 2 shows life expectancy by sex and age as compared with
the values obtained in the Auckland register and in the Basque
population with Markov models [12,31]. As was required, the
number of recurrent events totaled 25% of strokes, and the
distribution by age ﬁt well, with 25% of patients with strokes
hospitalized in Spain. The ﬁrst-ever stroke cumulative incidence
corresponded with the 75% of total stroke incidence in data
supplied by the Health Statistics Unit.
Research Outcomes Analysis
The prevalence in 2000 by sex and age group of all and depen-
dent patients is shown in Table 3. To allow comparison with
other populations, the adjusted rate according to the Segi world
population was also calculated. The results obtained with the
Markov model in 2000 are similar to estimates produced by the
DES model (Fig. 2). The overall volume of prevalence changed
from 316,031 individuals with the Markov model to 322,713
with DES, and the prevalence of dependent patients moved from
126,850 to 127,199. In addition, distribution by age group as
presented in Figure 2 ﬁts well and therefore clearly validates the
results. Nevertheless, the comparison with the Auckland rates
yielded prevalence ﬁgures that were 34% higher. When both
studies were standardized to the Segi world population, the
prevalence rates were 833 in Auckland and 558 in Spain. This
discrepancy is explained by the lower stroke incidence in Spain.
Notwithstanding the similar raw incidence rates by sex in
both populations (155 for men and 125 for women per 100,000
in Spain, and 148 for men and 124 for women per 100,000 in
Auckland) the Spanish incidence rates are lower when adjusted
by age, because the Spanish population in 2000 was older than
the population in Auckland in 1991. When we applied the
Spanish incidence rates to the Auckland population, the resulting
ﬁgure was 92 per 100,000 for both sexes, which means 32%
lower. Given the correspondence between incidence and preva-
lence, we can assess our model as externally validated because
the duration of stroke in patients according to sex and age is
similar (Table 2).
The impact of thrombolysis in the budget of the Spanish
health system as a whole during the 16 years since its introduc-
tion is presented in Table 4 and Figure 3. The savings are higher
than the intervention costs from 2006 on, and the difference
between them shows that the savings would increase every year
until 2015. The relationship between costs and savings is the
same when the model is constructed to reﬂect treatment of the
5% of patients with stroke, but the ﬁgures are halved (Fig. 3).
Saved costs, however, do not reach intervention costs when the
treatment is applied only to older individuals (Fig. 4).
Beneﬁt in effectiveness is related to the number of patients
who, as a result of the intervention, are autonomous at the end of
every year. These total 455 in the year 2000 and 4,031 in 2015
(Table 4). The net gains of these patients are 152 and 1349
quality-adjusted life-years, respectively.
Discussion
Two main conclusions derive from this study. From the economic
point of view, we found that the impact of thrombolysis on the
social and health services budget yields a net beneﬁt after 6 years.
In addition, the gain in health grows continuously, according to
the changes in the volume of dependent patients. Also, the valid-
ity of the DES model highlights the adequacy of this method-
ological approach in representing the epidemiology of stroke at a
population level and, therefore, in estimating the BIA.
If we had simulated a scenario with constant demographic
and epidemiologic parameters, the beneﬁt would have evolved
into a steady state with a constant beneﬁt after a warming-up
time. Nevertheless, because we took into account the aging of the
population in our model, the beneﬁt did not stabilize through
time. Because we applied the 2005 stroke rates by sex and age to
the predicted populations in successive years, raw incidence
increased progressively. The challenge to reproduce the 25% of
recurrent strokes and life expectancies of patients by sex and age
was successfully met by managing concurrent risks with Gomp-
ertz distributions. We acknowledge that it is difﬁcult for modelers
who are grounded in the design of Markov models to change
from establishing transition probabilities to calculating time until
event. This problem was solved by the Gompertz distribution on
the condition of age for time until recurrent stroke [28]. This
resulted in longer times until recurrent stroke for younger
patients and, consequently, produced a distribution of recurrent
strokes by age more in accordance with what we expected.
Table 2 Life expectancy (in years) of ﬁrst-ever stroke patients by age
and sex calculated with the Markov model, DES, and Auckland study
Age
Men Women
Markov DES Auckland Markov DES Auckland
50 11.92 15.58 14.20 15.64 21,29 15.90
60 8.06 9.67 8.50 11.23 13,66 9.50
70 4.92 5.39 5.20 6.93 7,74 5.80
80 2.66 2.53 3.00 3.49 3,45 3.20
DES, discrete event simulation.
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The comparison of the total prevalence obtained by means of
DES and Markov modeling supported the validation of the
method. In addition, distribution by age group as presented in
Figure 2 ﬁts well and therefore clearly validates the results.
Nevertheless, the comparison with the Auckland rates yielded
prevalence ﬁgures 34% that were higher. When both studies were
standardized to the Segi world population, the prevalence rates
were 833 in Auckland and 558 in Spain. This discrepancy is
Table 3 Stroke prevalence rates with conﬁdence intervals by sex, age, and level of disability calculated for the year 2000
Men
Overall Disabled
n
n/population
n
n/population
Age group Mean Upper CI Lower CI Mean Upper CI Lower CI
15–44 8,136 84.29 84.48 84.11 3,030 31.40 31.55 31.24
45–54 14,213 556.25 557.18 555.31 5,349 209.32 210.10 208.54
55–64 29,418 1,453.30 1,454.99 1,451.62 11,266 556.58 558.10 555.06
65–74 54,944 3,086.60 3,089.26 3,083.95 21,518 1,208.81 1,211.18 1,206.44
75–84 42,468 4,472.74 4,477.01 4,468.47 17,424 1,835.06 1,839.00 1,831.12
85+ 21,540 9,708.82 9,721.73 9,695.91 8,630 3,890.00 3,901.45 3,878.55
Total 170,719 842.39 842.79 841.99 67,217 331.67 332.04 331.30
Age-standardized* 700.96 273.14
Women
n
n/population
n
n/population
Age group Mean Upper CI Lower CI Mean Upper CI Lower CI
15–44 6,650 71.21 71.39 71.04 2,471.4 26.47 26.62 26.31
45–54 9,008 347.34 348.07 346.61 3,388.2 130.65 131.25 130.04
55–64 16,456 765.65 766.85 764.44 6,256.8 291.11 292.13 290.08
65–74 37,886 1,794.35 1,796.21 1,792.49 14,694.6 695.96 697.53 694.40
75–84 52,129 3,652.77 3,655.93 3,649.62 20,965.8 1,469.10 1,471.99 1,466.22
85+ 29,864 5,885.80 5,892.50 5,879.10 12,205.6 2,405.55 2,411.62 2,399.48
Total 151,994 722.13 722.50 721.76 59,982.4 284.98 285.31 284.65
Age-standardized* 440.61 170.87
Total
n
n/population
n
n/population
Age group Mean Upper CI Lower CI Mean Upper CI Lower CI
15–44 14,786 77.86 77.95 77.77 5,502 28.97 29.05 28.89
45–54 23,221 451.02 451.43 450.60 8,737 169.69 170.04 169.35
55–64 45,874 1,099.17 1,099.88 1,098.45 17,523 419.86 420.49 419.23
65–74 92,830 2,385.47 2,386.57 2,384.36 36,212 930.56 931.51 929.60
75–84 94,597 3,980.36 3,982.18 3,978.54 38,389 1,615.31 1,616.98 1,613.64
85+ 51,404 7,048.86 7,053.30 7,044.42 20,836 2,857.15 2,861.15 2,853.16
Total 322,713 781,12 781.31 780.93 127,199 307.88 308.06 307.71
Age-standardized* 558.33 217.04
*Age-standardized to the Segi world population, age 15 years and more.
CI, conﬁdence intervals; n, number of patients in the Spanish population who have suffered a stroke; n/population, prevalence per 100.000 population.
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Figure 2 Total stroke prevalence by age groups in
the Spanish population in the year 2000 based on
the Markov model, Auckland rates, and discrete
event simulation (DES) model.
Budget Impact with Discrete Event Simulation 73
explained by the lower stroke incidence in Spain. Notwithstand-
ing the similar raw incidence rates by sex in both populations
(155 for men and 125 for women per 100,000 in Spain, and 148
for men and 124 for women per 100,000 in Auckland) the
Spanish incidence rates are lower when adjusted by age, because
the Spanish population in 2000 was older than the population in
Auckland in 1991. When we applied the Spanish incidence rates
to the Auckland population, the resulting ﬁgure was 92 per
Table 4 Budget impact analysis of thrombolysis for 10% of strokes in the Spanish population from 2000 to 2005, 2010 and 2015
2000 2001 2002 2003 2004 2005 2010 2015
Stroke number 73,006 75,772 76,766 79,175 79,822 79,853 91,746 101,270
Dependent patients without thrombolysis 127,199 127,713 128,420 129,472 130,423 131,200 139,681 149,953
Dependent patients with thrombolysis (10%) 126,744 126,767 127,131 127,842 128,510 129,016 136,474 145,922
Difference in dependent patients 455 945 1,289 1,630 1,914 2,184 3,207 4,031
Number of thrombolysis 7,295 7,531 7,707 7,929 8,003 8,019 9,218 10,181
Difference in cost/dependent patient (€) 10,354 10,354 10,354 10,354 10,354 10,354 10,354 10,354
Cost/thrombolysis (€) 3,048 3,048 3,048 3,048 3,048 3,048 3,048 3,048
Saved costs (millions €) 4.7 9.8 13.3 16.9 19.8 22.6 33.2 41.7
Intervention costs (millions €) 19.6 20.3 20.8 21.4 21.6 21.6 24.8 27.4
Gain in effectiveness (QALYs) 152 316 431 546 640 731 1,073 1,349
QALYs, quality-adjusted life years.
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100,000 for both sexes, which means 32% lower. Given the
correspondence between incidence and prevalence, we can assess
our model as externally validated because the duration of stroke
in patients according to sex and age is similar (Table 2). Never-
theless, the small difference in the life expectancy of ﬁrst-ever
strokes by sex and age calculated by Markov and DES modeling
does not fully correlate with prevalence estimates. As Table 2
shows, life expectancies till 70 years obtained with DES model
are slightly higher than durations produced by Markov
approach. Therefore, prevalence estimates generated by DES
model should be slightly higher. Despite this small limitation, the
battery of results presented in this study illustrates the usefulness
of DES to represent the natural history of stroke.
This analysis was carried out from a comprehensive perspec-
tive that included both health and social authorities. A common
complaint about the application of this analysis in economic
evaluation is the difﬁculty of transferring resources from different
public institutions. In a scenario of limited budgets, there are
always social needs that must be met. Therefore, the adjustment
of budgets will not be achieved in the short term. Nonetheless,
the assessment of interventions that improve the level of
autonomy of individuals should not avoid any interaction
between health and social areas. If decisions concerning this
treatment are made from the perspective of the government drug
agency, the conclusion can be misleading because the rise in drug
cost is sustained. Society and its decision-makers must develop
broad criteria to ensure that common beneﬁt is maximized. The
perspective of most BIAs, however, is limited to the evolution of
drug expenditure as related to the treatment being assessed.
Hilden has underlined the need of the BIA to study the stream of
budget needs as a function of the prevalence of the disease states
[33]. The result of this thinking is that the standard epidemio-
logic paradigm (the study of disease incidence as a function of
prevalence of causal factors) is reversed. Accordingly, the deter-
mination of resources necessary to take care of dependent
patients relies on the prevalence by health states, which is a
consequence of the incidence of disabling diseases such as stroke
or Alzheimer’s disease [33,34].
The lack of standard methods has hampered the application
of a broad perspective. Our study shows that DES is a technique
that appropriately ﬁts the requisites of ﬂexibility in the represen-
tation of disease at a population level and of validity in the
achievement of useful results. Other methods such as Markov
models and differential equations have been used for the same
purpose [12,34,35]. One of the advantages of DES over Markov
models is that it is not necessary to recalculate the original cohort
and, consequently, DES avoids amplifying the error of predicted
populations. The Markov approach works well with current
populations, but its forward and backward projections can
produce a miscalculation. The characteristics of cases, or entities
in DES modeling, such as age and other outcome determinants,
are obtained according to the epidemiologic knowledge, and
these results in a natural representation of the population. Pro-
cesses in living beings are stochastic, and, thus, probabilistic
modeling, like DES, are advisable. The use of differential equa-
tions models in chronic diseases is constrained by two factors: the
deterministic use of parameters and the difﬁculty of constructing
and processing the equations systems. This type of model,
however, remains the mandatory approach for BIA in infectious
diseases because the “herd effect” is a key element in the under-
standing of that epidemiology [36]. Nevertheless, in chronic dis-
eases, differential equation models are more adequate for
epidemiologic analysis than for usual economic evaluation [34].
Modeling for cost-effectiveness analysis aims to compare
alternative interventions. The assessment of the efﬁciency of a
new treatment is based on the calculation of the incremental
cost-effectiveness ratio, which, obviously, does not depend on the
number of patients. On the contrary, population modeling
requires incidence ﬁgures as an input. Figures associated with
stroke are well known because an acute event occurs at the onset
of the disease process. In many diseases, however, accurate inci-
dence rates are not available. For example, in Parkinson’s and
Alzheimer’s disease, the incidence rate is difﬁcult to determine
because the appearance of symptoms is progressive. In hepatitis
C, the combination of silent transmission with changes in the
paths of spread from blood transfusions to sexual relationships
limits the estimation of accurate incidence rates. The lack of
empirical information can be resolved with expert opinion as a
source for estimates [37].
A subgroup analysis of elderly patients (more than 70 years
of age) reﬂected their shorter life expectancy, and thereafter
saved costs did not surpass the cost of thrombolysis during the
study period. This result can be invoked to establish an age limit
for patients to receive thrombolysis. Nevertheless, given the spe-
ciﬁc beneﬁt of thrombolysis in avoiding disability, the level of
autonomy should also be taken into account. Currently, the use
of thrombolysis in Spain is lower than the 10% that we applied
in our model. Some studies are exploring the option of extend-
ing the therapeutic window between 3 and 6 hours [38]. If that
period of time is shown acceptable for treatment, a higher pro-
portion of patients could be included to beneﬁt from throm-
bolysis. Currently, the delay in the recognition of symptoms by
patients increases the number of late arrivals to emergency
departments, making the administration of the rt-PA within 3
hours of the beginning of the event impossible in the majority of
cases. Initiatives such as the stroke code have been implemented
to reduce the time needed to carry out the CT scan and the
neurologic assessment [39]. The complete protocol entails
approximately 60 minutes, in addition to allowing 2 hours to
transport the patient to the hospital. The question that remains
unanswered is why the education of the general population that
has been shown to be so effective in the identiﬁcation of symp-
toms of myocardial infarction cannot be achieved in the case of
stroke. An obvious difﬁculty is that the clinical appearance of
stroke is much less speciﬁc than the symptoms of myocardial
infarction. Nevertheless, some clinical manifestations such as
motor or speaking disturbances can be easily related to stroke.
Public information campaigns, however, have not been carried
out. Public health policy involving stroke is still inﬂuenced by
fatalism. This work demonstrates that by improving the ability
of the general population to recognize stroke and seek rapid
medical contact, a better prognosis for patients will result.
Affordability is warranted as long as the balance is fully positive
after 6 years and the individual clinical prognosis is improved
from the beginning of the disease process.
This study is not free from limitations. In relationship with
the objective of the BIA, a key point was the percentage of
strokes treated with thrombolysis. We applied a ﬁgure that pro-
ceeded from an assumption and not from empirical sources. This
constraint is due to the lack of reliable data given the heteroge-
neous development of thrombolysis in different Spanish settings.
It must also be mentioned that inputs that determine the prog-
nosis of patients in the model come from 2000. Given the
improvement in hospital care, stroke patients evolve in 2009
better than 9 years ago. On the other side, the application of DES
model to BIA is still in an incipient stage and further research is
needed to standardize the process. Despite these shortcomings,
our study supports the conclusions that thrombolysis for stroke
is an affordable treatment and that DES modeling is a valid
method for BIA.
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